Encompass Health reports results for second quarter 2026

EHC delivers strong Q2 results and boosts buyback and guidance for 2026.

Risk flags

• ●The company provides no discussion of competitive threats or macroeconomic headwinds, leaving investors without context for potential revenue or margin pressure. This omission is notable given the sector's exposure to reimbursement changes and labor costs.
• ●Claims of market leadership and external recognition are not substantiated with data or documentation, raising questions about the accuracy or relevance of these reputational assertions. Without supporting evidence, these claims do not contribute to the investment case.
• ●Capital allocation signals are strong, but the announcement does not address the sustainability of buybacks or the impact of ongoing capital expenditures on leverage or future cash flows. The company reports $2,598.1 million in long-term debt and $3,996.4 million in total liabilities as of June 30, 2026, which could constrain future flexibility if operating performance falters.

Bottom line

Encompass Health's Q2 2026 results show robust revenue and EBITDA growth, with operational improvements translating into higher guidance for the full year. The $1 billion stock repurchase authorization and $145.8 million already repurchased signal management's confidence and provide near-term support for the share price. Expansion plans are concrete and scheduled for completion within the year, reducing execution risk. While financial disclosures are detailed and credible, unsupported claims about market leadership and awards have no bearing on the investment thesis. The absence of risk discussion is a gap, especially given sector uncertainties and the company's sizable debt load. For investors, the most important takeaway is that near-term financial momentum is real and guidance upgrades are grounded in actual performance, but ongoing monitoring of leverage and sector risks remains essential.

Announcement summary

(NYSE: EHC) Encompass Health Corporation announced an increase in its common stock repurchase authorization to $1 billion and reported net operating revenue of $1,597.4 million for the second quarter ended June 30, 2026. The company achieved Adjusted EBITDA of $348.0 million, income from continuing operations attributable to Encompass Health per diluted share of $1.55, and adjusted earnings per share of $1.55 for Q2 2026. Discharges for the quarter totaled 68,895, with same-store discharge growth of 2.8% and net patient revenue per discharge of $22,521. Cash flows provided by operating activities were $282.6 million, and adjusted free cash flow was $177.0 million for Q2 2026. The company increased its full-year 2026 guidance, with updated net operating revenue guidance of $6,410 to $6,490 million, Adjusted EBITDA guidance of $1,365 to $1,395 million, and adjusted earnings per share guidance of $6.02 to $6.25. The company repurchased $145.8 million of its common stock year to date and had approximately $188 million remaining under the prior authorization as of June 30, 2026.

Disagree with this article?